Boston Scientific’s SEISMIQ 4CE coronary intravascular lithotripsy catheter hit both primary endpoints in the 420-patient FRACTURE IDE trial at EuroPCR on May 19, with 93.3% MACE-freedom at 30 days against an 86.2% performance goal and 93.7% procedural success against an 85.8% goal. Endologix acquired the Pounce thrombectomy platform from Surmodics the same day, building on the platform’s existing FDA clearance and post-market evidence base. Lauxera Capital Partners closed €520 million in growth equity to fund European healthtech companies expanding into the US market, priced against commercial-stage clinical evidence rather than pre-clinical promise. Across all three signals, the structural input that unlocks each downstream event is the clinical evidence base. Founders who finish in regulated hardware design the IDE, the post-market evidence plan, and the comparator framing as architectural decisions made at the seed stage, not as functions resolved at trial design time.
If You Are Building a Company in This Environment
The default first-time medical device, diagnostics, defense-hardware, or industrial-robotics founder treats the pivotal trial as a regulatory exercise the clinical team will run when the device is engineering-ready, with the trial design negotiated against the FDA pre-submission meeting and the comparator framing settled in the protocol. The build-phase logic is that the technical capability is what the company is producing, that the clinical evidence is the gate the agency will price the asset against, and that the buyer-side and payer-side conversations are downstream events the company will navigate after the FDA authorization arrives. The three signals across May 19 reframe the logic. The FRACTURE readout that just gave Boston Scientific a credible challenge to the Shockwave calcium franchise was designed years earlier against a comparator-derived performance goal. The Pounce platform that just moved from Surmodics to Endologix carries the post-market evidence base that makes the carve-out commercially viable. The Lauxera growth round prices the European companies that already have commercial-stage CE-mark evidence and are now staging US pivotal trials against the same performance-goal logic the FRACTURE trial used.
Founders who finish in regulated hardware run the clinical-evidence plan as the structural input the operating plan is built around. They settle the comparator framing at the seed stage and design the engineering, the clinical protocol, and the post-market quality system against that framing. They run the pre-submission conversation against a comparator-derived performance goal that the agency reads as convincing and the buyer side reads as audit-ready. They build the post-market evidence base from the first commercial use so the carve-out, the platform extension, or the next-indication submission has the foundation the operating plan requires. They resource the evidence work as a Day-1 capital line equivalent in scale to the visible engineering work, because the evidence is what opens each downstream commercial door.
The version of the evidence decision that breaks first-time hard-tech founders is the one that settles the IDE design at trial-start time. The company arrives at the pre-submission meeting with the performance goal still being negotiated, the comparator framing still being argued, and the endpoint structure still being modeled against the operating plan’s preferred readout rather than against what the agency will read as convincing. The trial reads against a goal that under-credits the device, the readout lands as ambiguous to the agency, the buyer side discounts the asset against the comparator the company actually beats, and the cost shows up at the FDA submission, the term-sheet table, and the post-market commercial ramp simultaneously.
What the FRACTURE Trial Teaches About Trial Design as a Strategic Asset
FRACTURE is a useful current example of how IDE design choices compound into commercial positioning. Boston Scientific ran a prospective, non-randomized, single-arm study across 420 patients at 46 US and European sites with 2-year follow-up, pre-specified a 30-day MACE-freedom performance goal at 86.2% derived from the calcium-modification comparator evidence base, pre-specified a procedural-success goal at 85.8% with success defined as stent delivery with final residual stenosis below 50% and freedom from in-hospital MACE, and powered the study to read against both endpoints with conventional statistical margin. The readout landed at 93.3% MACE-freedom and 93.7% procedural success, with 100% successful stent delivery and 94.2% average stent expansion at the most calcified segment. The chief medical officer described the data as pivotal evidence for the regulatory submission, and the peripheral version of the platform was already cleared by FDA in 2025.
The architectural lessons travel across hard-tech categories. The trial design didn’t require head-to-head randomization against Shockwave, didn’t require non-inferiority statistics, and didn’t require the multi-thousand-patient cohort that an active-comparator randomized study would require. It required a comparator-derived performance goal the agency reads as the right reference, an endpoint structure that captures the clinical question the agency cares about, and a site mix that generalizes beyond a single high-volume center. The founders building a competitor in any device category where the incumbent has an established evidence base can run a similar single-arm pivotal against a comparator-derived performance goal, provided the comparator framing is settled with the agency in pre-submission and the trial is designed to deliver a margin the readout supports. The companies that finish in this environment treat the IDE as a strategic asset that the operating plan is built around, not as a regulatory deliverable the clinical team will figure out when the device is ready.
The Five Questions for the Clinical-Evidence Decision
The five-question framework in Founders Who Finish reframes what a credible operating plan actually requires the team to deliver in a regulated-hardware environment where pivotal evidence is the structural input that unlocks the FDA submission, the buyer-side conversation, and the growth-equity round. Each question maps to an architectural decision that compounds across the build phase into the participation profile the strategic acquirer, the payer, and the investor pricing the round all read at the moment the deal conversation begins.
Question 1
What are you actually finishing?
If the answer is a technical capability that the clinical team will validate once the device is engineering-ready, you are finishing a deliverable the buyer side will discount against an evidence base the company didn’t architect from the start. The finished business is the technical capability plus the clinical-evidence plan that produces the pivotal readout the agency reads as convincing, the buyer side reads as audit-ready, and the payer side reads as reimbursable. Founders who finish in regulated hardware design the IDE, the post-market evidence plan, and the comparator framing from initial company architecture and run the engineering, clinical, and commercial work against the evidence plan as the structural input the entire operating plan is built around.
Question 2
Who decides you are done?
The FDA reviewer decides whether the pivotal readout meets the pre-specified performance goal with the margin and the statistical structure the agency reads as convincing. The strategic acquirer’s clinical and commercial due-diligence team decides whether the evidence base supports the carve-out, the platform extension, or the post-acquisition commercial ramp. CMS decides whether the same evidence supports a coverage determination inside the reimbursement window the company is operating in. The growth-equity investor pricing the round decides whether the evidence base supports the commercial-stage thesis the term sheet is sized against. All four decisions read the same evidence base, and founders who finish design the evidence to read convincingly to all four at once.
Question 3
What does your evidence actually prove?
The pivotal evidence has to prove the specific clinical claim the device is built around, against a comparator-derived performance goal the agency settled in pre-submission, with an endpoint structure that captures the clinical question the agency cares about, across a site mix and operator diversity that generalizes beyond a single high-volume center. FRACTURE proves SEISMIQ delivers a MACE-freedom and procedural-success readout that exceeds the comparator-derived performance goal with a margin the agency reads as convincing. The carve-out value of the Pounce platform rests on the post-market evidence base Surmodics built across years of commercial use. The Lauxera growth round prices European companies whose CE-mark commercial-stage evidence reads as the foundation for the US ramp. Founders who finish design the evidence base to prove the claim the buyer, the agency, and the payer actually read, not the claim the operating plan would prefer to make.
Question 4
What does your path to clearance, reimbursement, and commercial scale actually look like?
The path to clearance runs through the pivotal readout against the comparator-derived performance goal the agency settled in pre-submission. The path to reimbursement runs through the same evidence base now read against the payer’s coverage standard, which after the CMS-FDA RAPID Coverage Pathway operationalization compresses to a 60 to 90 day window after FDA authorization. The path to commercial scale runs through the buyer-side conversation, the strategic-acquirer due-diligence audit, and the growth-equity round, each reading the same evidence base against its own standard. Founders who finish design the pathway, the evidence plan, the reimbursement architecture, and the commercial deal architecture as the same operating plan, with the IDE the structural input each downstream event is sized against.
Question 5
What does the finish line look like to your buyer, your payer, and the investor pricing the round?
Strategic acquirers, payers, and investors pricing medical device, diagnostics, defense-hardware, climate-hardware, and platform-tech businesses in 2026 read the clinical-evidence base as the structural input that justifies the deal structure, the coverage determination, and the round valuation. The FRACTURE readout, the Pounce platform’s post-market evidence, and the Lauxera fund’s pricing of European commercial-stage assets are the cleanest current public examples of how the environment concentrates participation behind the evidence discipline that produces auditable readouts against pre-specified performance goals. Founders who finish position the business to land inside the evidence-priced participation profile the environment reads, and the architectural discipline that produces the positioning has to be embedded from initial company architecture.
Founders Who Finish
The guide for founders building in regulated and capital-intensive markets
The five-question framework for building medical device, diagnostics, AI SaMD, defense, climate, and other hard-tech companies that finish what they start, in the regulatory, capital, and operating environment as it actually exists.
Get the Book